Biotech Startups

Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options. Its commercialized products include migraine therapies, and it advances a portfolio of early- to late-stage drug development programs.

4 investors

BIOIO develops a genetics-based platform for elucidating drug mechanisms of action, combining decades of research in pharmacology with big data and automation to accelerate drug discovery and development. The company serves pharmaceutical and biotech organizations seeking to understand how drugs work.

4 investors

The company builds "Biological Adapters" that integrate living neurons with AI foundation models to improve performance and reduce training cost, and it operates an algorithm discovery platform based on principles from biological neural systems. Its technology (TBC) targets applications such as computer vision, generative video, world models, robotics, and time-series prediction.

4 investors

Biomeme develops a mobile molecular testing platform that brings laboratory-grade PCR diagnostics to the point of need, serving clinical partners and organizations that need real-time detection of biological threats and diseases. The company operates a vertically integrated facility spanning biology, engineering, software, and manufacturing.

4 investors

Biomodal develops genomic and epigenomic sequencing technologies for life scientists and clinical researchers, enabling simultaneous analysis of genetic data and modified cytosine bases from a single DNA sample. The company's tools integrate pre- and post-sequencing workflows to capture both canonical and modified bases in the genome.

4 investors

Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease. Its pipeline includes TL1A, TL1A*IL-23p19 bispecific, and IL-25 antibodies with half-life extension technology.

4 investors

BioOra develops and manufactures CAR-T cell therapies from New Zealand, targeting patients with cancer who currently lack access to these treatments in their local regions. The company aims to improve treatment access, reduce delays, and enable scalable delivery of advanced cell therapies across underserved regions globally.

4 investors

Bioplaster develops biodegradable packaging materials and protective foam products that replace traditional plastics and paper for retail and textile industries. The company transforms environmental waste like sargassum into high-performance, sustainable packaging solutions.

4 investors

Biosense Technologies designs portable and affordable diagnostic devices for basic healthcare screening, leveraging digital technology to address gaps in access to diagnostic services across India's healthcare system.

4 investors

Biotalys develops protein-based biocontrol products for crop protection, giving farmers tools to prevent crop loss and extend post-harvest protection while reducing food waste. The agritech company builds a pipeline of products with novel modes of action targeting crop pests and diseases across the food value chain.

4 investors

Bloom Science is a clinical-stage biotech company developing live biotherapeutic products that replicate the effects of the ketogenic diet through the gut-brain axis. Its lead program, BL-001, targets obesity and Dravet syndrome, supported by the IrisRx discovery platform that uses gut commensal microbes and synthetic biology to develop therapies for metabolic and neurological disorders.

4 investors

Bluejay is a biotechnology company focused on therapeutic development. The page centers on its founder's background in drug discovery and life science venture investing but gives limited detail on the company's specific products.

4 investors

Blueprint Genetics is a genetic testing company that combines laboratory science, genetics, and bioinformatics to analyze and interpret genetic data. It operates as a global company with in-house software, cloud, and bioinformatics teams supporting its testing services.

4 investors

Bolt Threads was a manufacturer of biomaterials for personal care formulations. The company is no longer operating.

4 investors

Boston Bioprocess provides fermentation and bioprocess development services—including scale-up across 1.5L to 1,500L vessels, downstream process development, regulatory guidance, and tech transfer to CMOs—for companies bringing biomanufactured products to production. It also offers software and AI-driven process intelligence for lab execution, batch record management, scheduling, and results analysis.

4 investors

BRAINBox Solutions develops a multi-modality diagnostic approach for mild traumatic brain injury (mTBI), combining blood biomarker panels with tablet-based neurocognitive testing to produce an objective injury score and a prognosis of post-injury symptoms. The tools are aimed at clinicians for diagnosing concussion and predicting patient outcomes.

4 investors

BrainSpec develops software for analyzing and visualizing MR spectroscopy (MRS) neuroimaging data, aiming to make a non-invasive "virtual biopsy" available to clinicians and researchers. Its technology targets patient populations with conditions such as brain tumors, Alzheimer's disease, and Multiple Sclerosis.

4 investors

BreezeBio develops a programmable platform called NanoGalaxy for targeted delivery of genetic medicines, aiming to move genetic payloads to specific cells and tissues. The company operates in the biotech and genetic therapeutics space.

4 investors

Unreal Milk produces lab-grown whole cow milk using cellular agriculture technology. The company targets consumers seeking sustainable dairy alternatives.

4 investors

Bullseye Biosciences uses in-cell directed evolution to discover functional therapeutic molecules against challenging intracellular targets such as protein–protein interactions and transcriptional regulation. Its platform selects molecules like macrocyclic and stapled peptides based on their biological effect inside living cells, with applications in oncology, immunology, and other serious diseases.

4 investors

C2i Genomics develops a whole-genome sequencing platform that uses AI algorithms to build patient-specific cancer signatures for detecting minimal residual disease (MRD) and monitoring cancer. It serves oncology and cancer diagnostics use cases.

4 investors

CamGene Therapeutics develops RNA-based medicines, including mRNA, siRNA, and antisense oligonucleotides delivered via lipid nanoparticles, to treat the underlying cellular dysfunction that causes hearing loss. The company aims to modulate protein expression for regeneration and protection of cells in the cochlea as an accessible mass-market therapeutic.

4 investors

Canaery develops a nose-computer interface that combines animal olfaction with neurotechnology and AI to detect substances and diagnose diseases. The technology enables working animals to identify contraband, pests, and health conditions for security, pest control, and medical screening applications.

4 investors

Capsulomics offers Esopredict, a DNA methylation-based risk-stratification test that predicts progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma for gastroenterologists and pathologists. The test is used as a secondary option when the company's primary TissueCypher spatialomics test cannot provide results.

4 investors